SAN DIEGO and SYDNEY, Australia, May 23, 2011 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce it has received regulatory approval from the German health authority, BfArM, to begin the RESTORE clinical trial. Approval was also granted by the Brazilian Ministry of Health, CONEP, earlier this month.
